文献速递血栓与止血

COVID-19患者常出现高滴度非血小板活化性抗PF4/肝素IgG抗体

COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies.
PubMed 文献 · J Thromb Haemost · 2021-04-07

将5B9单抗或纯化IgG加入COVID-19血清后功能试验反应性未见增强,提示血清中不存在功能性抑制因子。结论认为COVID-19患者抗原试验强阳性常不伴血小板活化抗体,HIT诊断须以功能试验确认。

要点

  • COVID-19患者PF4/肝素抗原试验易呈强阳性,但常无血小板活化抗体。
  • 疑似HIT须以肝素依赖的血小板活化功能试验确认,避免过诊断。
  • 避免仅凭抗原试验强阳性即改用非肝素抗凝治疗。

核心结论

  • COVID-19患者常出现PF4/肝素抗原试验强阳性而不存在血小板活化抗体。
  • HIT诊断需确认肝素依赖的血小板活化抗体,以避免过诊断和非肝素抗凝过度治疗。

研究设计与样本

  • 样本分别进行抗原试验与肝素诱导血小板活化试验(HIPA)等功能试验。
  • 将5B9单抗加入COVID-19血清或对照血清,并检测纯化IgG组分的功能试验反应性。

主要发现

  • 9例抗原试验阳性者中仅3例HIPA也阳性。
  • 加入5B9后其反应性与对照血清保持一致。
  • 抗原试验强阳性而功能试验阴性的COVID-19血清纯化IgG,功能试验反应性较原血清未增高。

临床怎么用

  • 对疑似HIT的COVID-19患者应进行功能试验确认,不宜仅凭抗原试验强阳性诊断HIT。

局限性

  • 原文未报告更多方法学与随访细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a severe adverse reaction to heparin caused by heparin-dependent, platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies. Heparin is a cornerstone of treatment in critically ill COVID-19 patients. HIT antibodies can be detected by antigen tests and functional tests. Often strong reactivity in the antigen test is used as a surrogate marker for the presence of clinically relevant, platelet-activating antibodies. We observed an unexpectedly high percentage of COVID-19 patients, clinically suspected to have HIT, with high titer anti-PF4/heparin antibodies, but a negative functional test. OBJECTIVE: We investigated whether in COVID-19 patients a serum-derived factor inhibits the heparin-induced platelet activation test (HIPA). METHODS AND RESULTS: Twelve COVID-19 patients with suspected HIT were tested. Three samples tested negative in all assays; nine samples tested positive by antigen tests, among which only three tested also positive by HIPA. When we spiked COVID-19 serum or control serum with the human HIT antibody like monoclonal antibody 5B9, reactivity of 5B9 remained the same. Also, the purified IgG fractions of COVID-19 sera testing strongly positive in the PF4/heparin antigen test but negative in the functional test did not show increased reactivity in the functional test in comparison to the original serum. Both results make a functionally inhibitory factor in the serum/plasma of COVID-19 patients highly unlikely. CONCLUSION: COVID-19 patients often present with strong reactivity in PF4/heparin antigen tests without the presence of platelet-activating antibodies. Diagnosis of HIT requires confirmation of heparin-dependent, platelets activating antibodies to avoid overdiagnosis and overtreatment with non-heparin anticoagulants.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Brodard J, Kremer Hovinga JA, Fontana P, et al. COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. J Thromb Haemost. 2021. PMID: 33550713. doi:10.1111/jth.15262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。